New dual-target drugs combining cytotoxic agents with CAIX inhibitors were designed. Dual-targeting drugs may allow for specific drug delivery to hypoxic tumor areas. Increased binding affinity to CAIX was found for most of the dual-targeting drugs. Higher efficacy of dual-target ATR inhibitor was found in CAIX overexpressing cells. Design of alternative CAIX-targeting drugs may increase their therapeutic window.